ABL Bio’s partnership momentum with Eli Lilly accelerated this week as the South Korean bispecific antibody specialist unveiled a sweeping license, research, and collaboration agreement valued at up to USD $2.602 billion, followed by a separate KRW 22 billion equity investment from Lilly that further strengthens the multinational’s strategic commitment to ABL’s Grabody platform. Together, the deals represent one of the most significant cross-border biotech alignments emerging from Asia this year, signaling growing global interest in next-generation bispecifics and modular biologics.
Announced on November 12, the headline collaboration centers on ABL Bio’s Grabody platform, a bispecific antibody technology designed to support multiple modalities across oncology, metabolic disease, neurodegeneration, and immune disorders. Under the agreement, ABL Bio will receive a USD $40 million upfront payment following Hart–Scott–Rodino approval and is eligible for up to USD $2.562 billion in development, regulatory, and commercial milestone payments, along with tiered royalties on net sales if partnered molecules reach the market . The deal spans multiple programs and therapeutic categories, giving Lilly broad access to a discovery engine that ABL has spent years refining through both internal and partnered assets.
What You Need To Know
- Lilly and ABL Bio signed a multi-program Grabody platform collaboration worth up to USD $2.602B, including a $40M upfront and up to $2.562B in milestones.
- Lilly separately made a KRW 22B equity investment in ABL Bio to accelerate development of bispecific antibodies and ADCs.
- ABL Bio’s pipeline includes eight clinical programs, multiple partnerships, and promising Phase 1b immuno-oncology results.
- The dual deal signals long-term strategic alignment, giving Lilly broad access to a scalable next-gen biologics platform.
The scope of the collaboration signals clear confidence from Lilly, which continues to expand its immunology and obesity pipeline while seeking differentiated biologics platforms that can scale across indications. ABL Bio’s Grabody portfolio includes eight clinical programs such as ABL301 (SAR446159), ABL001 (tovecimig), ABL111 (givastomig), and ABL503 (ragistomig), with clinical activity underway in the United States, China, Australia, and Korea. ABL001 has already secured FDA Fast Track designation, and ABL111 recently reported encouraging Phase 1b data in combination with nivolumab and chemotherapy at ESMO GI 2025 evidence supporting the platform’s relevance in next-generation oncology combinations .
Just two days after announcing the landmark licensing collaboration, ABL Bio followed with additional news: Lilly will purchase 175,079 newly issued ABL Bio shares at KRW 125,900 per share, amounting to a KRW 22 billion investment. The proceeds will be used to expand the indications of the Grabody platform specifically targeting high unmet-need areas such as obesity and muscle diseases, where Lilly has established a dominant global footprint with incretin-based metabolic therapies. The investment shares will be subject to a one-year lock-up, signaling a longer-term strategic commitment rather than a transactional financing move. Funds will also support the development of novel bispecific ADCs, further strengthening ABL’s modality breadth .
Related news
Cidara Therapeutics Stock sky-Rockets on $9B Merck buyout
Taken together, the licensing partnership and equity investment reflect a deepening bilateral relationship that extends well beyond a traditional single-asset collaboration. For Lilly, the agreement represents an opportunity to diversify beyond classic monoclonal antibody engineering and enhance its presence in platforms capable of generating multi-target or multi-modal biologics. Lilly has increasingly prioritized partnerships that accelerate its discovery engine, building on recent investments across neurology, obesity, and oncology. Access to Grabody’s modular design aligns with the company’s stated objective to pursue differentiated approaches with broad therapeutic reach.
For ABL Bio, the collaboration marks a significant validation of a platform that has already been leveraged in multiple clinical programs. CEO Sang Hoon Lee emphasized that the agreements “demonstrate the continued expansion of modalities to which Grabody can be applied” and signaled ABL’s intent to push deeper into emerging therapeutic sectors, including muscle metabolic diseases and obesity a market where Lilly holds global leadership with blockbuster agents. By pairing scientific momentum with non-dilutive upfront capital and direct equity investment, ABL Bio now gains both financial reinforcement and global development capacity from one of the industry’s most formidable R&D organizations.
The multi-program framework also ensures that ABL Bio benefits from a long-term collaboration rather than a single-asset dependency. Each program carries its own milestone and royalty structure, providing multiple shots on goal as clinical development advances. Meanwhile, the equity investment provides near-term funding to support internal innovations and pipelines not directly tied to the Lilly collaboration.